J&J Moves Cell Therapy Into Mid-Stage Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The big pharma is developing CNTO 2476, human umbilical tissue-derived cells, for the treatment of dry age-related macular degeneration, the form of AMD with no current treatments.